Clinical trial · Observational
The Value of Follow-Up After Childhood Acute Lymphoblastic Leukaemia in Denmark - Family Perspectives
NCT03985215CI-TRIAL-00046998withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Overlapping with another danish questionnaire study
Summary
Brief summary (as posted)
The aim of the study is to evaluate the family perspective on follow-up programs after treatment for childhood acute lymphoblastic leukaemia. It is relevant when new follow-up programs are to be designed.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
| Surveys and Questionnaires | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Questionnaires | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Degree of parental concern
- timeFrame
- A single point in time when questionnaires are answered. The specific time point being 0-5 years after end of ALL treatment.
- description
- Self-designed questionnaire. Six items scored on a scale 1-7. Higher values represent a worse outcome. An average is calculated over the six items. An item evaluating the need for extra visits on a scale 1-3. Higher values represent a worse outcome. An item evaluating parental reported worries about the future on a scale 1-5. Higher values represent a worse outcome.
Secondary outcomes (4)
- measure
- Satisfaction with the follow-up program
- timeFrame
- A single point in time when questionnaires are answered. The specific time point being 0-5 years after end of ALL treatment.
- description
- Self-designed questionnaire. An item evaluating satisfaction the time interval between visits on a scale 1-3. Higher values represent a worse outcome.
- measure
- PedsQL scores
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Year
- Maximum age
- 15 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with B-precursor ALL and T-ALL enrolled in the NOPHO ALL-2008 trial * Age group 1.0-14.9 years. * Patients treated on one of the four Danish Paediatric oncology departments * Patients in the time period 0-5 years after cessation of maintenance therapy for ALL Exclusion Criteria: * A history of recurrence or second malignancies * Bone marrow transplantation * Down syndrome * If, due to language barriers, the family is unable to complete the questionnaire.
References
Publications (0)
Data not yet available
No reference posted for this study.